PRLD (Prelude Therapeutics) Moat Score: 3/10 (As of Jul. 07, 2026)


PRLD Prelude Therapeutics Inc PRLD
26 GF Score
Price $4.99
! 6 Warning Signs
View Full Analysis

What is Prelude Therapeutics Moat Score?

Prelude Therapeutics PRLD +1.63% 26 Moat Score is 3 as of Jul. 07, 2026. GuruFocus rates PRLD with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 1,395 Biotechnology companies, Prelude Therapeutics ranks better than 75.56% on this metric.

Prelude Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Prelude Therapeutics has No Moat: Prelude Therapeutics has weak competitive advantages with limited market share and brand strength. It relies on ongoing R&D but lacks significant intellectual property or regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Prelude Therapeutics might have No Moat - Very weak/transient advantages.

Prelude Therapeutics  (NAS:PRLD) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Prelude Therapeutics Moat Score Related Terms

PRLD vs DMAC, RCKT, CYDY: Moat Score Comparison

For the Biotechnology subindustry, Prelude Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prelude Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Prelude Therapeutics's Moat Score falls into.


PRLD
26GF Score
Prelude Therapeutics Inc PRLD
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Prelude Therapeutics (PRLD) has a Moat Score of 3 as of Jul. 07, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Prelude Therapeutics ranks #341 out of 1395 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Prelude Therapeutics' Moat Score too high?
Prelude Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Prelude Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Prelude Therapeutics ranks #341 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Prelude Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' Moat Score compare to DMAC and RCKT?
According to the Biotechnology industry distribution chart, Prelude Therapeutics ranks #341 out of 1395 companies for Moat Score. This places Prelude Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Prelude Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prelude Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prelude Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Prelude Therapeutics' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current Moat Score is 3 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prelude Therapeutics Business Description

Address 175 Innovation Boulevard, Wilmington, DE, USA, 19805
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
26GF Score

Get the complete analysis for PRLD

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.99
Price